Format

Send to

Choose Destination

Trends in the Use of Methadone, Buprenorphine, and Extended-Release Naltrexone at Substance Abuse Treatment Facilities: 2003-2015 (Update).

Authors

Alderks CE.

Source

The CBHSQ Report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2013-.
2017 Aug 22.

Excerpt

Background: Opioid addiction is a serious concern in the United States that can be treated successfully through medication-assisted treatment (MAT). Methadone, buprenorphine, and extended-release, injectable naltrexone are three medications that have been approved by the FDA for treatment of opioid use disorder. Method: National Survey of Substance Abuse Treatment Services data for years 2003 through 2015 were used to assess the usage and trends of MAT in facilities with and without OTPs. Results: This analysis found that the numbers of facilities utilizing MAT for opioid use disorder and the numbers of clients receiving each of the three medications has increased from 2003 to 2015. Conclusion: The increases in numbers of facilities providing MAT services and the increase in numbers of clients receiving MAT is an indication that facilities are responding to the demand for effective treatment for opioid use disorder. However, without a leveling off in the trends, there is indication of unmet need. Public health resources and education could be used to further increase access to treatment and inform the public about treatment options.

Supplemental Content

Support Center